Hemalkumar B Mehta1, Sneha D Sura2, Deepak Adhikari3, Clark R Andersen4, Stephen B Williams5, Anthony J Senagore1, Yong-Fang Kuo4, James S Goodwin6. 1. Department of Surgery, University of Texas Medical Branch, Galveston, Texas. 2. Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, Houston, Texas. 3. School of Public Health, Brown University, Providence, Rhode Island. 4. Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas. 5. Division of Urology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas. 6. Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas.
Abstract
BACKGROUND: This study was designed to adapt the Elixhauser comorbidity index for 4 cancer-specific populations (breast, prostate, lung, and colorectal) and compare 3 versions of the Elixhauser comorbidity score (individual comorbidities, summary comorbidity score, and cancer-specific summary comorbidity score) with 3 versions of the Charlson comorbidity score for predicting 2-year survival with 4 types of cancer. METHODS: This cohort study used Texas Cancer Registry-linked Medicare data from 2005 to 2011 for older patients diagnosed with breast (n = 19,082), prostate (n = 23,044), lung (n = 26,047), or colorectal cancer (n = 16,693). For each cancer cohort, the data were split into training and validation cohorts. In the training cohort, competing risk regression was used to model the association of Elixhauser comorbidities with 2-year noncancer mortality, and cancer-specific weights were derived for each comorbidity. In the validation cohort, competing risk regression was used to compare 3 versions of the Elixhauser comorbidity score with 3 versions of the Charlson comorbidity score. Model performance was evaluated with c statistics. RESULTS: The 2-year noncancer mortality rates were 14.5% (lung cancer), 11.5% (colorectal cancer), 5.7% (breast cancer), and 4.1% (prostate cancer). Cancer-specific Elixhauser comorbidity scores (c = 0.773 for breast cancer, c = 0.772 for prostate cancer, c = 0.579 for lung cancer, and c = 0.680 for colorectal cancer) performed slightly better than cancer-specific Charlson comorbidity scores (ie, the National Cancer Institute combined index; c = 0.762 for breast cancer, c = 0.767 for prostate cancer, c = 0.578 for lung cancer, and c = 0.674 for colorectal cancer). Individual Elixhauser comorbidities performed best (c = 0.779 for breast cancer, c = 0.783 for prostate cancer, c = 0.587 for lung cancer, and c = 0.687 for colorectal cancer). CONCLUSIONS: The cancer-specific Elixhauser comorbidity score performed as well as or slightly better than the cancer-specific Charlson comorbidity score in predicting 2-year survival. If the sample size permits, using individual Elixhauser comorbidities may be the best way to control for confounding in cancer outcomes research. Cancer 2018;124:2018-25.
BACKGROUND: This study was designed to adapt the Elixhauser comorbidity index for 4 cancer-specific populations (breast, prostate, lung, and colorectal) and compare 3 versions of the Elixhauser comorbidity score (individual comorbidities, summary comorbidity score, and cancer-specific summary comorbidity score) with 3 versions of the Charlson comorbidity score for predicting 2-year survival with 4 types of cancer. METHODS: This cohort study used Texas Cancer Registry-linked Medicare data from 2005 to 2011 for older patients diagnosed with breast (n = 19,082), prostate (n = 23,044), lung (n = 26,047), or colorectal cancer (n = 16,693). For each cancer cohort, the data were split into training and validation cohorts. In the training cohort, competing risk regression was used to model the association of Elixhauser comorbidities with 2-year noncancer mortality, and cancer-specific weights were derived for each comorbidity. In the validation cohort, competing risk regression was used to compare 3 versions of the Elixhauser comorbidity score with 3 versions of the Charlson comorbidity score. Model performance was evaluated with c statistics. RESULTS: The 2-year noncancer mortality rates were 14.5% (lung cancer), 11.5% (colorectal cancer), 5.7% (breast cancer), and 4.1% (prostate cancer). Cancer-specific Elixhauser comorbidity scores (c = 0.773 for breast cancer, c = 0.772 for prostate cancer, c = 0.579 for lung cancer, and c = 0.680 for colorectal cancer) performed slightly better than cancer-specific Charlson comorbidity scores (ie, the National Cancer Institute combined index; c = 0.762 for breast cancer, c = 0.767 for prostate cancer, c = 0.578 for lung cancer, and c = 0.674 for colorectal cancer). Individual Elixhauser comorbidities performed best (c = 0.779 for breast cancer, c = 0.783 for prostate cancer, c = 0.587 for lung cancer, and c = 0.687 for colorectal cancer). CONCLUSIONS: The cancer-specific Elixhauser comorbidity score performed as well as or slightly better than the cancer-specific Charlson comorbidity score in predicting 2-year survival. If the sample size permits, using individual Elixhauser comorbidities may be the best way to control for confounding in cancer outcomes research. Cancer 2018;124:2018-25.
Authors: Stefano Marventano; Giuseppe Grosso; Antonio Mistretta; Marta Bogusz-Czerniewicz; Roberta Ferranti; Francesca Nolfo; Gabriele Giorgianni; Stefania Rametta; Filippo Drago; Francesco Basile; Antonio Biondi Journal: Int J Colorectal Dis Date: 2014-07-27 Impact factor: 2.571
Authors: Stephen A Boorjian; Simon P Kim; Matthew K Tollefson; Alonso Carrasco; John C Cheville; R Houston Thompson; Prabin Thapa; Igor Frank Journal: J Urol Date: 2013-01-09 Impact factor: 7.450
Authors: Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag Journal: Ann Epidemiol Date: 2007-05-25 Impact factor: 3.797
Authors: Hemalkumar B Mehta; Shan Yong; Sneha D Sura; Byron D Hughes; Yong-Fang Kuo; Stephen B Williams; Douglas S Tyler; Taylor S Riall; James S Goodwin Journal: Health Serv Res Date: 2019-10-01 Impact factor: 3.402
Authors: Peiqi Wang; Susan M Hutfless; Eun J Shin; Christian Hartman; Sarah Disney; Christopher C Fain; Kathy P Bull-Henry; Daniel K Daniels; Tsion Abdi; Vikesh K Singh; Anthony N Kalloo; Martin A Makary Journal: JAMA Intern Med Date: 2019-07-01 Impact factor: 21.873
Authors: Patrick G Lyons; Jeff Klaus; Colleen A McEvoy; Peter Westervelt; Brian F Gage; Marin H Kollef Journal: J Oncol Pract Date: 2019-07-15 Impact factor: 3.840
Authors: Michael I Ellenbogen; Peiqi Wang; Heidi N Overton; Christine Fahim; Angela Park; William E Bruhn; Jennifer L Carnahan; Amy M Linsky; Seki A Balogun; Martin A Makary Journal: Drugs Aging Date: 2020-01 Impact factor: 3.923
Authors: Caitlin W Hicks; Peiqi Wang; William E Bruhn; Christopher J Abularrage; Ying W Lum; Bruce A Perler; James H Black; Martin A Makary Journal: J Vasc Surg Date: 2020-01-02 Impact factor: 4.268
Authors: Caitlin W Hicks; Courtenay M Holscher; Peiqi Wang; Chen Dun; Christopher J Abularrage; James H Black; Kim J Hodgson; Martin A Makary Journal: JACC Cardiovasc Interv Date: 2021-03-22 Impact factor: 11.075